"An insight into the future. Many people can have this, but not everyone can materialize this."
So says Celltrion Inc. president and CEO Woo Sung Kee of the company’s founder and chairman Jung Jin Seo....
Interview: Celltrion's Journey To The Top
Listen to this article
In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a global leader in antibody biosimilars. In this instalment of Scrip’s Leadership Series, CEO Woo Sung Kee talks about what it has taken for the company and its top management to achieve such rapid growth, its ambitions to enter the global top 10 biotech firms, and his own work philosophy.
Keep up with the top pharma business news of the week. On the go.
More from Business
- • By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
- • By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
